IBL will develop biomarker panels for use with Grifols' random-access, single-molecule counting platform, and the firms will collaborate on testing workflows.

Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols’ random access, single ...

IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a ...

In recent weeks, European markets have experienced significant turbulence, with the pan-European STOXX Europe 600 Index dropping 8.44%, marking its steepest decline in five years amid heightened ...